^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CCDC85A-ALK fusion

i
Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor, CCDC85A, Coiled-Coil Domain Containing 85A, KIAA1912, Coiled-Coil Domain-Containing Protein 85A
Entrez ID:
2years
Lung adenocarcinoma with an uncommon CCDC85A-ALK fusion responding to alectinib: A case report. (PubMed, J Cell Mol Med)
This is the first report of a lung adenocarcinoma patient harbouring a new uncommon anaplastic lymphocyte kinase fusion that showed a remarkable response to alectinib. NGS aids in selecting treatment in non-small cell lung cancer patients.
Journal
|
CCDC85A (Coiled-Coil Domain Containing 85A)
|
ALK fusion • CCDC85A-ALK fusion
|
Alecensa (alectinib)